Markt geschlossen -
Andere Börsenplätze
|
% 5 Tage | % 1. Jan. | ||
1’529 JPY | +0.39% | +1.09% | +8.83% |
Kurzporträt
Mitarbeiterzahl: 4 144
Umsatz nach Geschäftsbereich
JPY in Millionen | 2022 | Gewichtung | 2023 | Gewichtung | Delta |
---|---|---|---|---|---|
Prescription Drugs
93,3
%
| 249 579 | 93,7 % | 260 235 | 93,3 % | +4.27% |
Over-the-counter Drugs
3,8
%
| 9 780 | 3,7 % | 10 628 | 3,8 % | +8.67% |
Medical Equipment
2,2
%
| 5 184 | 1,9 % | 6 257 | 2,2 % | +20.70% |
Others
0,7
%
| 1 714 | 0,6 % | 1 919 | 0,7 % | +11.96% |
Umsatz je Region
JPY in Millionen | 2022 | Gewichtung | 2023 | Gewichtung | Delta |
---|---|---|---|---|---|
Japan
63,6
%
| 173 633 | 65,2 % | 177 373 | 63,6 % | +2.15% |
EMEA
18,8
%
| 42 899 | 16,1 % | 52 513 | 18,8 % | +22.41% |
Asia
8,6
%
| 19 813 | 7,4 % | 24 118 | 8,6 % | +21.73% |
China
7,7
%
| 27 197 | 10,2 % | 21 546 | 7,7 % | -20.78% |
Americas
1,3
%
| 2 715 | 1,0 % | 3 488 | 1,3 % | +28.47% |
Manager
Manager | Titel | Alter | Seit |
---|---|---|---|
Takeshi Ito
CEO | Chief Executive Officer | 64 | 01.04.82 |
Kazuo Koshiji
DFI | Director of Finance/CFO | - | - |
Akira Kurokawa
CHM | Chairman | 71 | 01.04.77 |
Mika Masunari
CMP | Compliance Officer | - | - |
Minori Hara
CTO | Chief Tech/Sci/R&D Officer | - | - |
Investor Relations Contact | - | - | |
Keizo Nakada
PRN | Corporate Officer/Principal | - | - |
Ippei Kurihara
SAM | Sales & Marketing | - | - |
Tomoki Yashiki
HRO | Human Resources Officer | - | - |
Hiro Izaka
AUD | Comptroller/Controller/Auditor | - | - |
Aufsichtsräte
Aufsichtsräte | Titel | Alter | Seit |
---|---|---|---|
Akira Kurokawa
CHM | Chairman | 71 | 01.04.77 |
Kanoko Oishi
BRD | Director/Board Member | 63 | 01.06.15 |
Noboru Kotani
BRD | Director/Board Member | 67 | 24.06.22 |
Yutaro Shintaku
BRD | Director/Board Member | 68 | 01.06.17 |
Director/Board Member | 69 | 01.06.18 | |
Takeshi Ito
CEO | Chief Executive Officer | 64 | 01.04.82 |
Tamie Minami
BRD | Director/Board Member | 65 | 24.06.22 |
Anteilsklasse
Vote | Menge | Streubesitz | Konzerneigene Aktien | Total Float | |
---|---|---|---|---|---|
Aktie A | 0 | 363 996 254 | 341 047 590 ( 93,70 %) | 12 792 169 ( 3,514 %) | 93,70 % |
Unternehmensbesitz
Name | Aktien | % | Bewertung |
---|---|---|---|
3 746 000 | 0,75% | 60 752 291 $ | |
EISAI CO., LTD. 0,32% | 949 500 | 0,32% | 38 997 598 $ |
737 469 | 0,20% | 7 487 007 $ | |
373 800 | 0,17% | 5 730 059 $ | |
259 040 | 0,00% | 2 664 939 $ | |
SEIKAGAKU CORPORATION 0,73% | 415 600 | 0,73% | 2 100 725 $ |
TOHO HOLDINGS CO., LTD. 0,09% | 69 050 | 0,09% | 1 666 197 $ |
QD LASER, INC. 1,06% | 444 480 | 1,06% | 1 597 657 $ |
SUZUKEN CO., LTD. 0,05% | 42 226 | 0,05% | 1 294 304 $ |
VITAL KSK HOLDINGS, INC. 0,25% | 128 474 | 0,25% | 1 066 195 $ |
Unternehmenskontakt
Santen Pharmaceutical Co., Ltd.
Grand Front Osaka Tower A, 25/F 4-20 Ofuka-cho
530-8552, Osaka
+81 6 7664 8621
http://www.santen.co.jpKonzerngesellschaften
Name | Kategorie und Branche |
---|---|
Santen Oy
Santen Oy Pharmaceuticals: MajorHealth Technology Santen Oy engages in the development, research, manufacture and marketing of pharmaceuticals, over-the-counter products, and medical devices. It specializes in ophthalmic pharmaceuticals. The company was founded on February 28, 1997 and is headquartered in Tampere, Finland. |
Pharmaceuticals: Major
|
Santen Pharmaceutical Spain SL
Santen Pharmaceutical Spain SL Medical DistributorsDistribution Services Part of Santen Pharmaceutical Co., Ltd., Santen Pharmaceutical Spain SL wholesales pharmaceutical products. The private company is based in Las Rozas, Spain. |
Medical Distributors
|
Sektor
Umsatz nach Geschäftsbereich
Umsatz je Region
Verlauf des Gewinns je Aktie
% 1. Jan. | Kap. | |
---|---|---|
+8.83% | 3.64 Mrd. | |
+21.85% | 546 Mrd. | |
-4.77% | 359 Mrd. | |
+16.97% | 323 Mrd. | |
+5.69% | 290 Mrd. | |
+13.68% | 234 Mrd. | |
+3.65% | 198 Mrd. | |
-11.12% | 194 Mrd. | |
+8.08% | 167 Mrd. | |
-3.40% | 157 Mrd. |
- Börse
- Aktien
- 864318 Aktie
- Unternehmen Santen Pharmaceutical Co., Ltd.